How to emerge from the conservatism in clinical research methodology?

Type de document :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1097/CCO.0000000000000399

PMID :

URL permanente :

http://hdl.handle.net/20.500.12210/17231

Titre :

How to emerge from the conservatism in clinical research methodology?

Auteur(s) :

Kotecki, Nuria [Auteur]
Penel, Nicolas [Auteur]

Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Awada, Ahmad [Auteur]

Titre de la revue :

Current opinion in oncology

Nom court de la revue :

Curr. Opin. Oncol.

Numéro :

29

Pagination :

400-404

Date de publication :

2017-09-01

ISSN :

1040-8746

Mot(s)-clé(s) en anglais :

solid tumors
innovative approach
new drugs
unmet need
network

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

OBJECTIVE: Despite recent changes in clinical research methodology, many challenges remain in drug development methodology. RESULTS: Advances in molecular biology and cancer treatments have changed the clinical research ...
Lire la suite >OBJECTIVE: Despite recent changes in clinical research methodology, many challenges remain in drug development methodology. RESULTS: Advances in molecular biology and cancer treatments have changed the clinical research landscape. Thus, we moved from empirical clinical oncology to molecular and immunological therapeutic approaches. Along with this move, adapted dose-limiting toxicities definitions, endpoints, and dose escalation methods have been proposed. Moreover, the classical frontier between phase I, phase II, and phase III has become unclear in particular for immunological approaches. So, investigators are facing major challenges in drug development methodology. CONCLUSIONS: We propose to individualize clinical research using innovative approaches to significantly improve patient outcomes and targeting what is considered unmet need. Integrating high level of translational research and performing well designed biomarker studies with great potential for clinical practice are of utmost importance. This could be performed within new models of clinical research networks and by building a strong collaboration between academic, cooperative groups, on-site investigators, and pharma.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:17:04Z

Historique des modifications